AAD: Bimekizumab Response Durable at Four Years for Moderate-to-Severe Psoriasis
After four years of bimekizumab treatment, more than six in 10 patients achieved and maintained complete skin clearance
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.